BLISOVI FE 1.5/30 (norethindrone acetate and ethinyl estradiol) by Teva is clinical pharmacology combination oral contraceptives act by suppression of gonadotropins. Approved for pregnancy in women. First approved in 2015.
Drug data last refreshed 19h ago
CLINICAL PHARMACOLOGY Combination oral contraceptives act by suppression of gonadotropins. Although the primary mechanism of this action is inhibition of ovulation, other alterations include changes in the cervical mucus (which increase the difficulty of sperm entry into the uterus) and the…
Worked on BLISOVI FE 1.5/30 at Teva? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.